GSK plc GSK

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

– Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Partners, a venture capital firm focused on transformative healthcare innovation, has appointed two longtime healthcare leaders to senior roles as it builds its next generation of companies and expands support for later-stage portfolio businesses. Sir Andrew Witty, former Chief Executive O

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Investment bank Jefferies has kept its ‘buy’ rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35%...

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.

GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren’t giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm’s price target to 2,200p from 2,000p on September 15. Berenberg said it is “increasingly optimistic” […]

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental […]

On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]

America Achieves today announced $3.3 million in new philanthropic commitments to Good Jobs Western North Carolina, a regional effort to help residents of 23 counties land good jobs and to build the talent systems that will keep that work going. The New York-based Rockefeller Foundation is committing $1 million over two years – the first national philanthropy to invest in this effort – triggering a matching two-year $2 million investment from John M. Belk Endowment. The North Carolina GlaxoSmith

GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company’s senior vice president and global head of Translational and Development Sciences. Speaking at

GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company’s growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company’s recent capital markets day. Brown said GSK’s strategic portfolio review identified

Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product Strategy Tina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective 1 October 2026. ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before being appointed Executive Vice President for Research &

DURHAM, N.C., September 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the continuation of its long-standing partnership with Prevention Access Campaign (PAC) – the founding organization behind the Undetectable = Untransmittable (U=U) movement. To celebrate 10 years of U=U, ViiV Healthcare is joining PAC to introduce "Undetectable Voices," a new digital storytelling and community engagement campaign that builds

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the past 5 years GSK shares have returned 58.4%, which puts real weight on whether the current earnings justify where the stock now trades. Recent deals in cancer therapies, including new T cell engager and...

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The acquisition of Chimagen's trispecific T cell-engager and the...

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to […]

DURHAM, N.C., September 15, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced more than $33 million in U.S. community grants awarded in 2026. These investments support 230 community-based organizations in 110 cities across 36 states and territories, including Puerto Rico, working to ensure that people and communities most disproportionately impacted by HIV have access to the support they need.